Ease: Empagliflozin Beneficial In Type 1 Diabetes Dka A Risk | Latest News RSS feed

Ease: Empagliflozin Beneficial In Type 1 Diabetes Dka A Risk - Latest News


EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk

BERLIN — The sodium-glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) improved glycemic control and weight in type 1 diabetes, but also increased ... read more

Positive Results for Empagliflozin in Type 1 Diabetes Trials

Results from the Phase 3 EASE ... higher with empagliflozin 10mg (4.3%) and 25mg (3.3%), DKA incidence was comparable between empagliflozin 2.5mg (0.8%) and placebo (1.2%). “Given the risk of diabetic ... read more

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

The EASE program results were published online ... Canada. "Given the risk of diabetic ketoacidosis for people with type 1 diabetes, the 2.5 mg empagliflozin dose warrants consideration, as it ... read more

Looking for another news?


Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

The number of adjudicated diabetic ketoacidosis events was comparable between empagliflozin 2.5 mg and placebo and higher than placebo in adults with type 1 diabetes on empagliflozin 10 mg and 25 mg. ... read more


US FDA approves Jardiance tabs to reduce risk of cardiovascular death in adults with type 2 diabetes

We believe that Jardiance is an important treatment option for this patient population." Jardiance is not for people with type 1 diabetes or people with diabetic ketoacidosis ... their increased risk ... read more

Lexicon Likely Looking At Even More Competition In Type 1 Diabetes

Lexicon could really use some good news, as the company ... s somewhat cryptic release regarding its EASE-2 and EASE-3 trials of Jardiance in Type 1 diabetes back in the summer created some hope that ... read more

FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

Sotagliflozin, works by inhibiting the proteins SGLT1 and SGLT2 to help regulate blood ... exceeding $450 million for type 1 diabetes by 2024. The FDA panel members in January had raised concerns of ... read more

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes

Apart from incidence of DKA, the safety profile observed in the EASE ... The benefit-risk profile of empagliflozin has been well-established in its approved indications. Empagliflozin is currently not ... read more

Diabetes Download: What Should I Know Before Starting the Ketogenic Diet With Diabetes?

But though it is generally accepted as beneficial in type 2 diabetes, the risk of the keto diet in people with type 1 is considered much greater. This is due to the increased possibility of going from ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us